Immunology & allergy
Immune system & allergy clinical trials
Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We’re tracking 6,230 recruiting studies in this area right now.
By phase
- Not applicable3,143
- Phase 21,065
- Phase 1821
- Phase 1/Phase 2445
- Phase 3424
- Phase 4238
- Phase 2/Phase 394
Top conditions
- Multiple Sclerosis341
- Multiple Myeloma332
- Asthma194
- Lymphoma182
- Rheumatoid Arthritis141
- Type 1 Diabetes133
- Atopic Dermatitis128
- Systemic Lupus Erythematosus125
- Acute Lymphoblastic Leukemia122
- HIV Infections116
- Chronic Lymphocytic Leukemia100
- Autoimmune Diseases81
- Follicular Lymphoma74
- Diabetes Mellitus, Type 169
- Hodgkin Lymphoma67
- Rheumatoid Arthritis (RA)66
- Leukemia64
- Acute Myeloid Leukemia62
Leading sponsors
- Institute of Hematology & Blood Diseases Hospital, China91
- National Institute of Allergy and Infectious Diseases (NIAID)90
- National Cancer Institute (NCI)74
- Assistance Publique - Hôpitaux de Paris70
- M.D. Anderson Cancer Center63
- Novartis Pharmaceuticals63
- AstraZeneca57
- City of Hope Medical Center47
- Mayo Clinic46
- Memorial Sloan Kettering Cancer Center44
Where studies are running
- California494
- Maryland196
- Alabama175
- Florida143
- Arizona140
- New York123
- Massachusetts119
- Texas118
- Illinois81
- Colorado77
Recruiting studies6,230 total
- NCT05567133Recruiting
Study markers that predict how sarcoidosis changes over time
This study follows adults with sarcoidosis to see which body “risk signals” (biomarkers) can predict whether the disease will get better or worse. It may help doctors monitor sarcoidosis more closely and choose the right treatment sooner.
Baltimore, MarylandAges 19 years+ - NCT05566769Recruiting
Test a phone tool for self-checks in NMOSD
This study tests a digital (phone) tool that helps people with NMOSD do unsupervised self-assessments between clinic visits. It looks at how well the tool works and whether it is safe and understandable for patients.
Los Angeles, CaliforniaAges 18 years+ - NCT05567198Recruiting
Testing hormone shots to protect ovaries during lupus chemotherapy
This study looks at whether a monthly/3-month hormone medicine (a “GnRH shot”) can help protect ovaries in people with lupus who are treated with cyclophosphamide. It also compares this to lupus patients who do not receive the ovarian-protecting shot, using questionnaires to track outcomes.
Bethesda, MarylandAges 18–120 - NCT05572229RecruitingPhase 2
Teclistamab treatment for older adults with multiple myeloma
This Phase 2 trial studies how well teclistamab works when used in combination for people age 65 and older with multiple myeloma. It aims to see whether this treatment can control the cancer safely in older patients who may not do high-dose chemotherapy or stem cell transplant.
AmiensAges 65 years+ - NCT05573802RecruitingPhase 1/Phase 2
Belantamab and other medicines for new multiple myeloma
This early-phase study tests how safe and effective belantamab mafodotin is when combined with lenalidomide and dexamethasone, plus a medicine called nirogacestat, in people with newly diagnosed multiple myeloma who cannot have stem cell transplant. It may help shrink the cancer and improve outcomes, while doctors track side effects.
AthensAges 18 years+ - NCT05575882Recruiting
Skin cream trial to prevent relapses in very dry eczema skin
This trial tests whether a cosmetic cream can reduce eczema flare-ups and is comfortable/safe to use on very dry, irritated, eczema-prone skin. It’s mainly for children who have had recent flare-ups and moderate eczema severity.
Ciudad Autónoma de Buenos Aire, Ciudad Autónoma de Buenos AireAges 6 months–15 years - NCT05576350Recruiting
Coaching to reduce risky drinking and HIV risk
This study tests an intervention (coaching/skills training) to help reduce risky alcohol use and reduce behaviors that increase HIV risk. It may help you if you drink in an at-risk way and may benefit from HIV prevention like PrEP.
New Haven, ConnecticutAges 18–35 - NCT05578105Recruiting
Study of autoimmune polyglandular disease genetics in Taiwan
This study looks at how common autoimmune polyglandular syndrome type II is in Taiwan and what genetic differences may be involved. It uses past hospital visit records and focuses on people who had a specific pattern of autoimmune conditions.
TaipeiAges 20 years+ - NCT05578716Recruiting
Study growth and allergies in formula-fed vs breastfed infants
This trial compares how babies grow and whether they develop allergy or digestive symptoms in breastfed infants versus infants fed a special hydrolysed formula. It may help doctors understand which feeding approach supports healthy development early in life.
MalmöAges 4 weeks–2 months - NCT05581147Recruiting
Thyroid health in Klinefelter syndrome
This study looks at how the thyroid gland works and how it looks on ultrasound in people with classic (non-mosaic) 47,XXY Klinefelter syndrome. It may help doctors understand thyroid-related problems in this condition by comparing test results, symptoms, and imaging.
RomaAges 1–80 - NCT05580666RecruitingPhase 3
Lower death risk by adding azithromycin to HIV treatment
This Phase 3 study tests whether adding azithromycin helps people with advanced HIV disease live longer. You would start (or restart or adjust) HIV treatment within 4 weeks and may also receive azithromycin or a comparison approach to see if outcomes improve.
AbidjanAges 18 years+ - NCT05581030RecruitingPhase 1
Newly diagnosed ALL: testing a treatment after Hyper-CVAD
This Phase 1 study looks at a treatment approach for people newly diagnosed with Philadelphia-negative B- or T-cell acute lymphoblastic leukemia (ALL) after completing a specific chemotherapy course called Hyper-CVAD 1A. It aims to see if the treatment can be given safely and how well it may work for this type of leukemia.
Tampa, FloridaAges 18–50 - NCT05583071RecruitingPhase 2
Testing a four-drug plan for primary brain lymphoma
This Phase 2 trial studies methotrexate, tafasitamab, lenalidomide, and rituximab for primary B-cell lymphoma that starts in the brain/spinal fluid. It aims to see how well this combination works for people who cannot have certain high-dose stem cell treatment.
Stuttgart, Baden-WurttembergAges 18–99 - NCT05583617RecruitingPhase 1/Phase 2
Testing multiple treatments for multiple myeloma after prior therapy
This early-phase study tests how safe and effective several treatment approaches are for people with multiple myeloma who have already had other treatments. Depending on your myeloma features and prior care, a study drug combination may be offered to try to control the disease.
Randwick, New South WalesAges 18 years+ - NCT05584631RecruitingPhase 1
Switching IVIG to weekly SCIG for CIDP treatment
This Phase 1 study compares IVIG given through an IV versus SCIG given under the skin, for people with CIDP. It aims to find the right weekly SCIG dose based on your current IVIG dose, which could make treatment more convenient.
New Brunswick, New JerseyAges 18–65 - NCT05584124RecruitingPhase 2
Brain stimulation treatment for lasting fatigue after stroke
This trial tests a non-painful brain stimulation method (repetitive magnetic pulses) to see if it can reduce fatigue that continues long after a stroke. It may help people whose stroke fatigue has lasted more than six months and who can safely undergo repeated sessions.
Decatur, GeorgiaAges 34–80 - NCT05584488Recruiting
Study of immune and allergy patterns over time
This study follows people with suspected or known inherited immune/allergy problems by collecting health information and blood. It may help researchers understand how immune systems and allergies behave over time and support future studies.
New York, New YorkAges Up to 99 years - NCT05585983RecruitingPhase 4
Flu shot in newly diagnosed type 1 diabetes patients
This trial checks whether giving a flu vaccine to people who were just diagnosed with type 1 diabetes affects their health and immune response. It may help doctors understand if flu vaccination is safe and useful soon after diagnosis.
AalborgAges 7–17 - NCT05587894RecruitingPhase 2
Testing optimized COVID antiviral treatment in immunocompromised adults
This study tests the best combination and timing of antiviral medicines for people with COVID-19 who have weakened immune systems. It aims to improve outcomes in people with mild to moderate illness.
Bordeaux, BordeauxAges 16 years+ - NCT05590416Recruiting
Adalimumab for early Vogt-Koyanagi-Harada eye inflammation
This trial studies adalimumab to treat a rare, fast-onset eye inflammation called Vogt-Koyanagi-Harada disease. It may help people who can’t use strong steroid treatments or whose disease is not improving quickly with them.
Tianjin, Tianjin MunicipalityAges 18–70 - NCT05592015RecruitingPhase 2
Ruxolitinib for T-cell large granular leukemia
This Phase 2 study tests ruxolitinib, a targeted medicine, to improve outcomes in T-cell large granular lymphocytic leukemia (T-LGLL). It is for people whose disease is causing symptoms or who have already tried other treatment, with specific blood, infection, and medication requirements.
Boston, MassachusettsAges 18 years+ - NCT05593081Recruiting
Study of sudden type 1 diabetes after rapid symptom onset
This trial studies people who develop severe, fast-onset “type 1 diabetes” with body-wide stress (ketosis/ketoacidosis) soon after symptoms start. It aims to better understand this condition and how to care for it early.
Quanzhou, FujianAges Any age - NCT05594706Recruiting
Anhydroglucitol test in children with type 1 diabetes
This trial studies how anhydroglucitol behaves in children with type 1 diabetes who use insulin pump therapy and glucose monitoring. Your team will compare measurements over about a year to see if this marker could be useful for tracking diabetes control.
Geneva, Canton of GenevaAges 2–18 - NCT05594797RecruitingPhase 2
BCMA CAR-T for multiple myeloma that came back or stopped working
This trial tests a one-time BCMA CAR-T cell treatment for people with multiple myeloma that relapsed or did not respond well to prior treatments. It may help by training your own immune cells to recognize and attack myeloma cells.
Shanghai, Shanghai MunicipalityAges 18–75
Common questions
- How many immune system & allergy clinical trials are recruiting?
- Clin2 is tracking 6,230 recruiting immunology & allergy studies from the U.S. registry right now, out of 9,742 we cover in this area in total.
- What does “Immune system & allergy” cover here?
- Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We group each study into immune system & allergy based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a immune system & allergy trial near me?
- Use the search to filter immune system & allergy studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.